Literature DB >> 12471126

HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity.

Florence A Castelli1, Cécile Buhot, Alain Sanson, Hassane Zarour, Sandra Pouvelle-Moratille, Céline Nonn, Hanne Gahery-Ségard, Jean-Gérard Guillet, André Ménez, Bertrand Georges, Bernard Maillère.   

Abstract

Among HLA-DP specificities, HLA-DP4 specificity involves at least two molecules, HLA-DPA1*0103/DPB1*0401 (DP401) and HLA-DPA1*0103/DPB1*0402 (DP402), which differ from each other by only three residues. Together, they are present worldwide at an allelic frequency of 20-60% and are the most abundant human HLA II alleles. Strikingly, the peptide-binding specificities of these molecules have never been investigated. Hence, in this study, we report the peptide-binding motifs of both molecules. We first set up a binding assay specific for the immunopurified HLA-DP4 molecules. Using multiple sets of synthetic peptides, we successfully defined the amino acid preferences of the anchor residues. With these assays, we were also able to identify new peptide ligands from allergens and viral and tumor Ags. DP401 and DP402 exhibit very similar patterns of recognition in agreement with molecular modeling of the complexes. Pockets P1 and P6 accommodate the main anchor residues and interestingly contain only two polymorphic residues, beta86 and beta11, respectively. Both positions are almost dimorphic and thus produce a limited number of pocket combinations. Taken together, our results support the existence of three main binding supertypes among HLA-DP molecules and should significantly contribute to the identification of universal epitopes to be used in peptide-based vaccines for cancer, as well as for allergic or infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471126     DOI: 10.4049/jimmunol.169.12.6928

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign.

Authors:  Massimo Andreatta; Morten Nielsen
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

2.  HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

Authors:  Marcel van Lith; Rosanna M McEwen-Smith; Adam M Benham
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

3.  Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs.

Authors:  Gema Díaz; Benito Cañas; Jesús Vazquez; César Nombela; Javier Arroyo
Journal:  Immunogenetics       Date:  2004-11-24       Impact factor: 2.846

4.  Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells.

Authors:  Junbao Yang; Laurel Huston; Deanna Berger; Nancy A Danke; Andrew W Liu; Mary L Disis; William W Kwok
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

5.  An asymmetric model of heterozygote advantage at major histocompatibility complex genes: degenerate pathogen recognition and intersection advantage.

Authors:  Rick J Stoffels; Hamish G Spencer
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

Review 6.  The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy.

Authors:  Matthieu Perreau; E J Kremer
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

7.  Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

Authors:  Makito Tanaka; Marcus O Butler; Sascha Ansén; Osamu Imataki; Alla Berezovskaya; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

8.  A HLA-DRB supertype chart with potential overlapping peptide binding function.

Authors:  Arumugam Mohanapriya; Satish Nandagond; Paul Shapshak; Uma Kangueane; Pandjassarame Kangueane
Journal:  Bioinformation       Date:  2010-01-20

9.  MultiRTA: a simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes.

Authors:  Andrew J Bordner; Hans D Mittelmann
Journal:  BMC Bioinformatics       Date:  2010-09-24       Impact factor: 3.169

10.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.